May 7, 2012
According to the results of the interim analysis of the all-case post-marketing surveillance(PMS)for the rheumatoid arthritis (RA) treatment abatacept (brand name: Orencia), it was revealed that in its 24-week observation period, the incidence of serious adverse drug reactions (ADRs) for...read more